Isradipine Extended-Release Tabs Rx
Generic Name and Formulations:
Isradipine 5mg, 10mg; ext-rel tabs.
Indications for Isradipine Extended-Release Tabs:
Do not crush or chew. Initially 5mg once daily, alone or with a thiazide diuretic. May increase by 5mg/day at 2–4 week intervals; max 20mg/day.
CHF. GI narrowing (CR). Pregnancy (Cat.C). Nursing mothers: not recommended.
β-blockers may potentiate heart failure. Severe hypotension possible with fentanyl.
Calcium channel blocker (CCB) (dihydropyridine).
Dizziness, edema, palpitations, fatigue, flushing, dyspnea, GI upset, tachycardia, rash, pollakiuria, weakness, headache.
Formerly known under the brand name Dynacirc CR.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma